메뉴 건너뛰기




Volumn 20, Issue 6, 2014, Pages 1458-1468

Cancer drug development and the evolving regulatory framework for companion diagnostics in the european union

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; ANTINEOPLASTIC AGENT;

EID: 84896512336     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1571     Document Type: Article
Times cited : (43)

References (33)
  • 1
    • 84896525622 scopus 로고    scopus 로고
    • Similarities and differences in the oncology drug approval process between fda and european union with emphasis on in vitro companion diagnostics
    • Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res 2014; 20:1445-52.
    • (2014) Clin Cancer Res , vol.20 , pp. 1445-1452
    • Senderowicz, A.M.1    Pfaff, O.2
  • 4
    • 84896514438 scopus 로고    scopus 로고
    • European Medicines Agency Committee for Human Medicinal Products. Reflection paper on methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection (draft). London (UK): The Agency; 2011 Jun. Report No.: EMA/446337/2011
    • European Medicines Agency, Committee for Human Medicinal Products. Reflection paper on methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection (draft). London (UK): The Agency; 2011 Jun. Report No.: EMA/446337/2011.
  • 5
    • 84896513241 scopus 로고    scopus 로고
    • European Medicines Agency Committee for Human Medicinal Products. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development (draft). London (UK): The Agency; 2010 Jun. Report No.: EMA/CHMP/641298/
    • European Medicines Agency, Committee for Human Medicinal Products. Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development (draft). London (UK): The Agency; 2010 Jun. Report No.: EMA/CHMP/641298/2008.
    • (2008)
  • 6
    • 84896522908 scopus 로고    scopus 로고
    • European Medicines Agency Committee for Human Medicinal Products. CHMP assessment report: Pixuvri (pixantrone). London, (UK): The Agency; 2012 Feb. Report No.: EMA/309145/2012
    • European Medicines Agency, Committee for Human Medicinal Products. CHMP assessment report: Pixuvri (pixantrone). London, (UK): The Agency; 2012 Feb. Report No.: EMA/309145/2012.
  • 7
    • 84896535145 scopus 로고    scopus 로고
    • European Medicines Agency, Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. London (UK): The Agency; 2012 Dec. Report No.: EMA/CHMP/205/95/Rev.4
    • European Medicines Agency, Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. London (UK): The Agency; 2012 Dec. Report No.: EMA/CHMP/205/95/Rev.4.
  • 8
    • 84896498314 scopus 로고    scopus 로고
    • Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ L 331, p. 1-37 (December 7, 1998)
    • Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ L 331, p. 1-37 (December 7, 1998).
  • 9
    • 84896500987 scopus 로고    scopus 로고
    • Global Harmonization Task Force, Study Group 1 of the Global Harmonization Task Force. Principles for in vitro diagnostic (IVD) medical devices classification. 2008 Jul. Report No.: GHTF/SG1/N045
    • Global Harmonization Task Force, Study Group 1 of the Global Harmonization Task Force. Principles for in vitro diagnostic (IVD) medical devices classification. 2008 Jul. Report No.: GHTF/SG1/N045.
  • 11
    • 84896500742 scopus 로고    scopus 로고
    • Amendments adopted by the European Parliament on 22 October 2013 on the proposal for a regulation of the European Parliament and of the Council on in vitro diagnostic medical devices (COM(2012) 0541-C7-0317/2012-2012/0267(COD))
    • Amendments adopted by the European Parliament on 22 October 2013 on the proposal for a regulation of the European Parliament and of the Council on in vitro diagnostic medical devices (COM(2012)0541-C7-0317/2012-2012/0267(COD)). 2013.
    • , vol.2013
  • 12
    • 84896496628 scopus 로고    scopus 로고
    • European Commission. Citizens' summary: EU proposals on medical devices [Internet]. Brussels, Belgium: The Commission Available from
    • European Commission. Citizens' summary: EU proposals on medical devices [Internet]. Brussels, Belgium: The Commission; 2012. Available from: http://ec.europa.eu/health/medical-devices/files/revision-docs/ citizen-summary-20120926en.pdf.
    • , vol.2012
  • 14
    • 80053484515 scopus 로고    scopus 로고
    • Integrating predictive biomarkers and classifiers into oncology clinical development programmes
    • Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov 2011;10:735-48.
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 735-748
    • Beckman, R.A.1    Clark, J.2    Chen, C.3
  • 15
    • 84895905845 scopus 로고    scopus 로고
    • Biomarker enrichment strategies: Matching trial design to biomarker credentials
    • Epub 2013 Nov 26. doi: 10.1038/nrclinonc.2013.218
    • Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2013;11:81-90. Epub 2013 Nov 26. doi: 10.1038/nrclinonc.2013.218.
    • (2013) Nat Rev Clin Oncol , vol.11 , pp. 81-90
    • Freidlin, B.1    Korn, E.L.2
  • 16
    • 27744537954 scopus 로고    scopus 로고
    • Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
    • Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11: 7872-8.
    • (2005) Clin Cancer Res , vol.11 , pp. 7872-7878
    • Freidlin, B.1    Simon, R.2
  • 17
    • 69949102133 scopus 로고    scopus 로고
    • Confirmatory adaptive designs with bayesian decision tools for a targeted therapy in oncology
    • Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009;28:1445-63.
    • (2009) Stat Med , vol.28 , pp. 1445-1463
    • Brannath, W.1    Zuber, E.2    Branson, M.3    Bretz, F.4    Gallo, P.5    Posch, M.6
  • 18
    • 34648840242 scopus 로고    scopus 로고
    • Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
    • Wang SJ, O'Neill RT, HungHM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44.
    • (2007) Pharm Stat , vol.6 , pp. 227-244
    • Wang, S.J.1    O'Neill, R.T.2    Hung, H.M.3
  • 20
    • 84896499871 scopus 로고    scopus 로고
    • European Medicines Agency. CHMP assessment report: Xalkori (crizotinib). London (UK): The Agency; 2012 Jul. Report No.: EMA/CHMP/497137/2012
    • European Medicines Agency. CHMP assessment report: Xalkori (crizotinib). London (UK): The Agency; 2012 Jul. Report No.: EMA/CHMP/497137/2012.
  • 21
    • 84896509866 scopus 로고    scopus 로고
    • European Medicines Agency. CHMP assessment report: Vectibix (panitumumab). London (UK): The Agency; 2007 Dec. Report No.: EMEA/CHMP/394299/2007
    • European Medicines Agency. CHMP assessment report: Vectibix (panitumumab). London (UK): The Agency; 2007 Dec. Report No.: EMEA/CHMP/394299/2007
  • 22
    • 84896532982 scopus 로고    scopus 로고
    • European Medicines Agency. CHMP assessment report: Iressa (gefitinib). London (UK): The Agency; 2009 Jul. EMEA/CHMP/563746/2008
    • European Medicines Agency. CHMP assessment report: Iressa (gefitinib). London (UK): The Agency; 2009 Jul. EMEA/CHMP/563746/2008.
  • 23
    • 37349069551 scopus 로고    scopus 로고
    • Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of psi
    • Wang SJ. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 2007;6: 283-96.
    • (2007) Pharm Stat , vol.6 , pp. 283-296
    • Wang, S.J.1
  • 24
    • 84896529457 scopus 로고    scopus 로고
    • Product information: Glivec (imatinib). London (uk): The agency; 2013 oct. Available from
    • European Medicines Agency. Product information: Glivec (imatinib). London (UK): The Agency; 2013 Oct. Available from: http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000406/ human-med-000808.jsp&mid=WC0b01ac058001d124.
    • European Medicines Agency
  • 25
    • 84896514290 scopus 로고    scopus 로고
    • European Medicines Agency. CHMP assessment report: Caprelsa (vandetanib). London UK: The Agency; 2011 Nov. Report No.: EMA/128076/2012
    • European Medicines Agency. CHMP assessment report: Caprelsa (vandetanib). London, UK: The Agency; 2011 Nov. Report No.: EMA/128076/2012.
  • 27
    • 84859438079 scopus 로고    scopus 로고
    • Hurdles in anticancer drug development from a regulatory perspective
    • Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012;9:236-43.
    • (2012) Nat Rev Clin Oncol , vol.9 , pp. 236-243
    • Jonsson, B.1    Bergh, J.2
  • 28
    • 78449294101 scopus 로고    scopus 로고
    • Assessing the clinical utility of diagnostics used in drug therapy
    • Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 2010;88:765-73.
    • (2010) Clin Pharmacol Ther , vol.88 , pp. 765-773
    • Woodcock, J.1
  • 30
    • 84896535710 scopus 로고    scopus 로고
    • The health technology assessment of companion diagnostics: Experience of nice
    • Byron SK, Crabb N, George E, Marlow M, Newland A. The health technology assessment of companion diagnostics: experience of NICE. Clin Cancer Res 2014;20:1469-76.
    • (2014) Clin Cancer Res , vol.20 , pp. 1469-1476
    • Byron, S.K.1    Crabb, N.2    George, E.3    Marlow, M.4    Newland, A.5
  • 31
    • 84896537994 scopus 로고    scopus 로고
    • The proposed eu ivd regulation and its impact on diagnostic development. Scrip regulatory affairs. (21 jun 2013). 32. Mansfield ea.fda perspective on companion diagnostics: An evolving paradigm
    • Le Gledic S, Malek S. The proposed EU IVD Regulation and its impact on diagnostic development. Scrip Regulatory Affairs. (21 Jun 2013). 32. Mansfield EA.FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-7.
    • (2014) Clin Cancer Res , vol.20 , pp. 1453-1457
    • Le Gledic, S.1    Malek, S.2
  • 32
    • 84896510407 scopus 로고    scopus 로고
    • European Commission. Impact assessment on the revision of the regulatory framework for medical devices. Brussels (Belgium): The Commission; 2012 Sept. Report No.: SWD ( 2012) 273 final
    • European Commission. Impact assessment on the revision of the regulatory framework for medical devices. Brussels (Belgium): The Commission; 2012 Sept. Report No.: SWD (2012) 273 final.
  • 33
    • 84896498789 scopus 로고    scopus 로고
    • European Commission, Enterprise and Industry Directorate-General. Recast of the Medical Devices Directives: summary of responses to the public consultation. Brussels (Belgium): The Commission; 2008 Dec. Report No.: ENTR/F/3/D( 2008) 39582
    • European Commission, Enterprise and Industry Directorate-General. Recast of the Medical Devices Directives: summary of responses to the public consultation. Brussels (Belgium): The Commission; 2008 Dec. Report No.: ENTR/F/3/D(2008) 39582.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.